Company / Revenue
ARS Pharmaceuticals, Inc. Revenue History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$84.3M
FY2025
5-year range
$30.0K / $89.1M
FY2021-FY2025
Trend
-5.5%
vs FY2024
Sector context
#109 of 155
Health Care
What the data says
At $84M, ARS Pharmaceuticals, Inc.'s revenue ranks #109 of 155 in the Health Care sector. Improved from $30,000 to $84M over the past 2 years.
Based on SEC 10-K filings.
$84M in FY2025 with a 3-year CAGR of +148.3%.
Improved from $30,000 to $84M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +148.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#109 of 155 in Health CareTop 70% of 155This company $84.3M Sector average $4.5B
▼
-98.1% below sector average
Key checks
Key Insights
- 3-year CAGR of +148.3%, indicating consistent growth.
- In FY2025, revenue decreased 5.5% year-over-year.
- Ranks #109 out of 155 companies in the Health Care sector.
- Peak revenue was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $84.3M | -5.5% |
| FY2024 | $89.1M | +297063.3% |
| FY2023 | $30.0K | -99.5% |
| FY2022 | $5.5M | +0.0% |
| FY2021 | $5.5M | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026